Suppr超能文献

一种新型含3-甲氧基水杨醛缬氨酸配体的大环四核氧化钒(V)配合物的抗肿瘤特性

Antitumor Properties of a New Macrocyclic Tetranuclear Oxidovanadium(V) Complex with 3-Methoxysalicylidenvaline Ligand.

作者信息

Turtoi Mihaela, Anghelache Maria, Patrascu Andrei A, Deleanu Mariana, Voicu Geanina, Raduca Mihai, Safciuc Florentina, Manduteanu Ileana, Calin Manuela, Popescu Delia-Laura

机构信息

"Medical and Pharmaceutical Bionanotechnologies" Laboratory, Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, 8 B.P. Hasdeu, 050568 Bucharest, Romania.

Department of Inorganic Chemistry, Faculty of Chemistry, University of Bucharest, 23 Dumbrava Roşie, 020464 Bucharest, Romania.

出版信息

Biomedicines. 2022 May 24;10(6):1217. doi: 10.3390/biomedicines10061217.

Abstract

A wide variety of metal-based compounds have been obtained and studied for their antitumor activity since the intensely used cytostatic drugs (e.g., cisplatin) failed to accomplish their expected pharmacological properties. Thus, we aimed to develop a new vanadium-based drug and assess its antitumor properties using the human hepatocarcinoma (HepG2) cell line. The compound was synthesized from vanadyl sulfate, DL-valine, and -vanillin and was spectrally and structurally characterized (UV-Vis, IR, CD, and single-crystal/powder-XRD). Compound stability in biological media, cell uptake, and the interaction with albumin were assessed. The mechanisms of its antitumor activity were determined compared to cisplatin by performing cytotoxicity, oxidative and mitochondrial status, DNA fragmentation, β-Tubulin synthesis investigation, and cell cycle studies. Herein, we developed a macrocyclic tetranuclear oxidovanadium(V) compound, [(VO)(L)(CHO)], having coordinated four Schiff base (HL) ligands, 3-methoxysalicylidenvaline. We showed that [(VO)(L)(CHO)]: (i) has pH-dependent stability in biological media, (ii) binds to albumin in a dose-dependent manner, (iii) is taken up by cells in a time-dependent way, (iv) has a higher capacity to induce cell death compared to cisplatin (IC = 6 μM vs. 10 μM), by altering the oxidative and mitochondrial status in HepG2 cells. Unlike cisplatin, which blocks the cell cycle in the S-phase, the new vanadium-based compound arrests it in S and G2/M-phase, whereas no differences in the induction of DNA fragmentation and reduction of β-Tubulin synthesis between the two were determined. Thus, the [(VO)(L)(CHO)] antitumor mechanism involved corroboration between the generation of oxidative species, mitochondrial dysfunction, degradation of DNA, cell cycle arrest in the S and G2/M-phase, and β-Tubulin synthesis reduction. Our studies demonstrate the potent antitumor activity of [(VO)(L)(CHO)] and propose it as an attractive candidate for anticancer therapy.

摘要

自从广泛使用的细胞毒性药物(如顺铂)未能实现其预期的药理特性以来,人们已经获得并研究了多种金属基化合物的抗肿瘤活性。因此,我们旨在开发一种新型钒基药物,并使用人肝癌(HepG2)细胞系评估其抗肿瘤特性。该化合物由硫酸氧钒、DL-缬氨酸和香草醛合成,并通过光谱和结构表征(紫外可见光谱、红外光谱、圆二色光谱和单晶/粉末X射线衍射)。评估了该化合物在生物介质中的稳定性、细胞摄取以及与白蛋白的相互作用。通过进行细胞毒性、氧化和线粒体状态、DNA片段化、β-微管蛋白合成研究以及细胞周期研究,确定了其与顺铂相比的抗肿瘤活性机制。在此,我们开发了一种大环四核氧化钒(V)化合物[(VO)(L)(CHO)],它配位了四个席夫碱(HL)配体,即3-甲氧基水杨醛缬氨酸。我们表明[(VO)(L)(CHO)]:(i)在生物介质中具有pH依赖性稳定性,(ii)以剂量依赖性方式与白蛋白结合,(iii)以时间依赖性方式被细胞摄取,(iv)通过改变HepG2细胞中的氧化和线粒体状态,与顺铂相比具有更高的诱导细胞死亡的能力(IC = 6 μM对10 μM)。与在S期阻断细胞周期的顺铂不同,新型钒基化合物将细胞周期阻滞在S期和G2/M期,而两者之间在诱导DNA片段化和减少β-微管蛋白合成方面没有差异。因此,[(VO)(L)(CHO)]的抗肿瘤机制涉及氧化物种的产生、线粒体功能障碍、DNA降解、S期和G2/M期的细胞周期阻滞以及β-微管蛋白合成减少之间的协同作用。我们的研究证明了[(VO)(L)(CHO)]的强大抗肿瘤活性,并提出它是一种有吸引力的抗癌治疗候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48bc/9220379/03b9283f749b/biomedicines-10-01217-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验